Press Release (ePRNews.com) - AUCKLAND, New Zealand - Jan 31, 2016 - Pharmaceutical Brands Ltd, portfolio manufacturer and marketer of trademarked personal care products, specialises in Sun Protection and Insect Repellent product ranges.
Poised for regional and international expansion, this restructure ensures that new product development, new market development and capitalisation of “Dragon’s Den” winning equity investment results can be harnessed.
From November 2015, the company will be known as Pharmexa Limited, a New Zealand-based manufacturing and marketing company.
Pharmexa Limited will carry the flagship brands UltraBlock, BiteGuard, AfterBurn, AfterBite, LipMate, LiceGuard and LiceGone, pitching their products on efficacy and price to challenge global and regional pharmaceutical competitors in the Sun Protection and Insect Repellent markets with before and after lotions.
“Our intention,” says CEO Julian Price, “is to help improve the lives of people worldwide from debilitating diseases like Dengue Fever, Ross River Fever, West Nile Fever and Elephantitis.
“We stand strongly by our products and their performance, and as we develop streamlined delivery to more channels, more markets and more countries, we will need the structure, infrastructure and investment to do this.”
Quality Management starts with the formulations, their copyright, trademarks and globally recognised performance ratings from Dermatest Pty Ltd, Australia. “UltraBlock SPF 50+” Sun Screen has achieved an outstanding empirically validated 80.81 SPF rating!
Pharmexa has several new products ready to launch in international markets which will compete for a growing share of a product category worth 8 Billion USD annually. “We are aiming for 25% of this market within 6 years,” says CEO Julian Price.
Pharmexa has also upgraded all Military formulations and will be approaching major military organisations worldwide.
New Packaging design launched in November 2015 simply reinforces the new era of presentation and marketing focus.
“It’s highly competitive,” says CEO Mr Julian Price, “but this company has massive growth potential in every market worldwide due to niche marketing and formulation points of difference.
“With more than five world markets expressing strong interest and the Dragons’ Den opportunity still on the table, now is the time to welcome anyone wishing to ethically invest long-term.”
For more information, go to www.pharmexa.co.nz For sales enquiries and distribution rights, please contact Mr Julian Price, PO Box 38, Clevedon, Auckland, New Zealand or phone +64 9 437 2116 or email firstname.lastname@example.org.
DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.